Tag: MONOGRAPH

  • Mecasermin rinfabate

    Recombinant human insulin-like growth factor-1 and insulin-like growth factor binding protein-3 equimolar binary complex (rhIGF-1/rhIGFBP-3)

    A recombinant equimolar binary protein complex of human IGF-1 and its principal binding protein IGFBP-3, developed by Insmed as iPLEX for subcutaneous replacement therapy in severe primary IGF-1 deficiency and subsequently investigated in amyotrophic lateral sclerosis and complications of extreme prematurity.

    Abstract

    Mecasermin rinfabate (International Nonproprietary Name; brand name iPLEX) is a pharmaceutical-grade equimolar binary complex of recombinant human insulin-like growth factor-1 (rhIGF-1, 70 amino acids, 7,649 Da) and recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3, 264 amino acids, approximately 28,700 Da unglycosylated), produced in Escherichia coli expression systems and formulated for subcutaneous injection at a combined molecular weight of approximately 36,381 daltons. The complex was designed to replicate the physiological binary association of IGF-1 with its most abundant circulating binding protein, thereby extending the plasma half-life of administered IGF-1 from approximately 10 to 20 minutes (free rhIGF-1) to approximately 13 to 21 hours (complexed form), reducing hypoglycemic risk relative to unbound IGF-1, and enabling once-daily subcutaneous dosing in contrast to the twice-daily regimen required for mecasermin (rhIGF-1 alone, marketed as Increlex). Upon subcutaneous administration, the binary complex associates with endogenous acid-labile subunit (ALS) to form the approximately 150 kDa ternary complex that represents the principal physiological reservoir of circulating IGF-1, thereby normalizing the IGF-1 axis in patients with deficient endogenous production.

    The compound received United States Food and Drug Administration approval on December 12, 2005 (NDA 021884) for the treatment of growth failure in children with severe primary insulin-like growth factor-1 deficiency (Primary IGFD) or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone. The approved dose range was 0.5 to 2.0 mg/kg administered once daily by subcutaneous injection, titrated to achieve physiological IGF-1 levels measured 8 to 18 hours post-dose. Clinical development was conducted in two cohort studies enrolling 36 children and adolescents with primary IGFD, predominantly growth hormone receptor deficiency (Laron syndrome), demonstrating statistically significant dose-dependent increases in height velocity from a pre-treatment baseline of approximately 3 to 4 cm/year to 6 to 9 cm/year during the first year of treatment.

    The commercial trajectory of mecasermin rinfabate was truncated by patent litigation. In March 2007, Insmed Incorporated settled a patent infringement action brought by Tercica (the manufacturer of mecasermin/Increlex) by agreeing to withdraw iPLEX from the United States market for all short stature indications and to abandon its European regulatory application for these uses. The settlement extinguished the primary commercial indication. Insmed subsequently investigated mecasermin rinfabate in amyotrophic lateral sclerosis (ALS) under both clinical trial and compassionate-use frameworks; a Phase II randomized controlled trial in 330 ALS patients failed to demonstrate benefit on muscle strength, need for tracheostomy, or survival at the end of a two-year treatment period. More recently, the rhIGF-1/rhIGFBP-3 complex (under the development name of the successor product) has been investigated by Shire (now Takeda) and collaborators in extremely preterm infants for prevention of retinopathy of prematurity and other complications of prematurity, with a Phase 2 randomized controlled trial (NCT01096784) demonstrating a 53 percent decrease in severe bronchopulmonary dysplasia but no reduction in retinopathy of prematurity severity.

    The pharmacology of mecasermin rinfabate is that of its constituent IGF-1 moiety acting through the type 1 IGF receptor (IGF-1R), a transmembrane receptor tyrosine kinase that activates the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase (MAPK/ERK) signaling cascades to promote linear growth, cellular proliferation, differentiation, and survival. The IGFBP-3 moiety serves as a pharmacokinetic modulator, extending half-life and buffering against acute hypoglycemia, while also exerting IGF-independent effects including proapoptotic activity through nuclear receptor interactions and antiproliferative signaling in certain cellular contexts. The principal adverse events at approved doses are hypoglycemia (31 percent), headache (22 percent), arthralgia, injection site reactions, and lymphadenopathy. Safety data beyond 21 months of continuous treatment have not been established. This monograph reviews the molecular composition, development history, mechanism of action, pharmacokinetics, clinical evidence base across all studied indications, handling considerations, adverse-event profile, and a comparative assessment of five IGF-1 axis therapeutics against mecasermin rinfabate on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1423Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Tetracaine

    Plain-language summaryIntrigue 45 / 100

    Tetracaine (Pontocaine) is a long-acting ester local anesthetic from the 1930s, made by adding an n-butyl substituent to the para-amino position of procaine. That single modification raises potency about ten-fold and stretches duration to 2 to 3 hours, suitable for spinal anesthesia. Three modern clinical contexts: topical ophthalmic anesthesia (the 0.5 percent eye drop for tonometry, foreign body removal, corneal procedures), topical anesthesia of mucous membranes for ENT and bronchoscopy preparation, and spinal anesthesia (though levobupivacaine and bupivacaine spinal have largely displaced tetracaine in modern practice). Topical eutectic mixtures with lidocaine (LMX, Ametop) provide effective skin anesthesia. The principal safety concerns are systemic toxicity from absorbed mucosal doses and the historical cardiac collapse cases during spinal anesthesia. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Ester local anesthetic (long-acting)

    A long-acting butyl-substituted ester local anesthetic used principally in topical ophthalmic and spinal anesthesia.

    Abstract

    Tetracaine (2-(dimethylamino)ethyl 4-(butylamino)benzoate; CAS 94-24-6; molecular formula C15H24N2O2; molecular weight 264.36) is an ester-class local anesthetic synthesized in the 1930s and introduced clinically as Pontocaine. The n-butyl substitution at the para-amino position of the procaine scaffold substantially increases lipid solubility, potency, and duration of action; tetracaine is roughly 10-fold more potent than procaine and produces 2 to 3 hour blocks suitable for spinal anesthesia. Mechanism is voltage-gated sodium channel block with state-dependent kinetics. Hepatic and plasma cholinesterase hydrolysis produces the para-aminobenzoic acid metabolite shared with other ester anesthetics, with the same allergic considerations. Clinical use centers on three contexts: topical ophthalmic anesthesia (0.5 percent ophthalmic drops for tonometry, foreign body removal, and corneal procedures), topical anesthesia of mucous membranes including ENT and bronchoscopy preparation, and spinal anesthesia (the long duration suits longer surgical cases though levobupivacaine and bupivacaine spinal have largely displaced tetracaine in modern practice). Topical eutectic mixtures with lidocaine (LMX, AmetopTM) provide effective skin anesthesia. The principal safety concerns are systemic toxicity from absorbed topical doses (particularly across mucous membranes where rapid absorption can produce LAST events) and the historical association with cardiovascular collapse during spinal anesthesia in the era before standard intervention algorithms. Maximum dose for spinal anesthesia is approximately 20 mg; topical mucous membrane dosing should be limited to under 50 mg total. Tetracaine has been studied extensively in topical pediatric venipuncture preparation as part of LMX-4 formulation.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1315Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Cortagen

    Khavinson tetrapeptide bioregulator (Ala-Glu-Asp-Pro)

    A four-residue synthetic peptide developed by the Khavinson group as a cerebral cortex bioregulator, part of the Russian short-peptide bioregulator class.

    Abstract

    Cortagen (Ala-Glu-Asp-Pro; CAS 254749-42-7; molecular weight 414.41) is a four-residue synthetic peptide developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson as a representative of the short-peptide bioregulator class derived from cortexin (a porcine cerebral cortex extract registered as a medicine in the Russian Federation). The Khavinson program isolated active fragments from organ-specific peptide extracts and characterized synthetic tetrapeptide and tripeptide analogs as the molecular basis of the parent extract’s activity, including Cortagen for cerebral cortex, Pinealon (Glu-Asp-Arg) for pineal/CNS, Epitalon (Ala-Glu-Asp-Gly) for pineal, Vilon (Lys-Glu) for thymus, and several others. The proposed mechanism is direct DNA binding of the short peptides at promoter regions of tissue-specific genes, modulating transcription in a cell-type-restricted manner; published Russian-language work characterizes binding to specific GC-rich regulatory regions and effects on transcription factor recruitment. Pro-cognitive and neuroprotective activities of Cortagen are reported in rodent models of cerebral hypoxia, traumatic brain injury, and stress; Russian clinical reports describe efficacy in vegetative-vascular dystonia, post-traumatic asthenia, and discirculatory encephalopathy at intramuscular doses of 5 to 10 mg over 5 to 10 day courses. The Khavinson bioregulator class is registered as medicines in the Russian Federation and a small number of CIS jurisdictions; FDA, EMA, and most Western regulatory authorities have not reviewed the class. The principal limitation on the evidence base is the dominance of the originating laboratory’s publications and the limited scale of clinical evidence relative to what would be required for Western regulatory approval. Investigators should weight the evidence accordingly.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1331Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • PTD-DBM

    Wnt pathway activator and CXXC5-Dishevelled interaction inhibitor

    A research-grade peptide that disrupts the CXXC5-Dishevelled negative regulatory complex on the canonical Wnt pathway, studied for hair follicle stimulation and tissue regeneration.

    Abstract

    PTD-DBM (protein transduction domain conjugated to Dishevelled-binding motif; DBM derived from the Dishevelled-PDZ-binding C-terminus of CXXC5; molecular weight approximately 4 kDa as a synthetic conjugate) is a research-grade peptide developed at Yonsei University in South Korea by Kang-Yell Choi and colleagues as a tool for activating canonical Wnt signaling at the level of the Dishevelled scaffold. The canonical Wnt pathway is a developmental signaling system that drives stem cell self-renewal, tissue regeneration, and (importantly for hair) the anagen phase of the hair follicle cycle. CXXC5 is a negative regulator of canonical Wnt signaling that binds Dishevelled at a defined motif and prevents Dishevelled-mediated signal propagation; loss of CXXC5 in knockout mice produces enhanced Wnt signaling, accelerated hair cycle entry, and resistance to age-related hair thinning. The PTD-DBM peptide is designed to mimic the CXXC5 Dishevelled-binding motif and competitively displace endogenous CXXC5 from Dishevelled, releasing canonical Wnt signal flow. The PTD (HIV-Tat-derived protein transduction domain) enables cell membrane crossing of the otherwise impermeable peptide. Reported activities in rodent and human ex vivo hair follicle models include accelerated anagen induction, increased hair shaft length, and protection against chemotherapy-induced and androgenetic alopecia in rodent models. Topical formulation with the valproic acid co-treatment (KDC-MN-1348) has been explored as a synergistic Wnt-activating combination. The compound is research-grade and not approved by any regulatory authority; clinical translation through Yonsei University spin-out CXC5 has been in early stages. Reconstitution requires aqueous buffer with co-solvent for the peptide-PTD conjugate; topical delivery in the hair-follicle context is the principal route under investigation.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1347Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Ecnoglutide

    cAMP-biased glucagon-like peptide-1 receptor agonist with preferential Gs/cAMP signaling over beta-arrestin recruitment

    A long-acting, fatty acid-conjugated GLP-1 analog developed at Sciwind Biosciences as the first cAMP signaling-biased GLP-1 receptor agonist, distinguished from semaglutide and other marketed incretin mimetics by selective activation of the Gs/adenylyl cyclase/cAMP cascade with markedly reduced beta-arrestin recruitment and GLP-1 receptor internalization, yielding sustained receptor surface availability and enhanced glycemic and weight-reducing efficacy in clinical populations.

    Abstract

    Ecnoglutide (XW003; CAS 2459531-73-6; molecular formula C194H304N48O61; molecular weight 4284.84 g/mol) is a lipopeptide analog of human glucagon-like peptide-1 (GLP-1) (7-37) engineered with an alanine-to-valine substitution at position 8 and a C18 fatty diacid conjugated to the epsilon-amino group of lysine 30 through a gamma-glutamate and dual 2-(2-(2-aminoethoxy)ethoxy)acetic acid linker. Designed and developed at Sciwind Biosciences (Hangzhou, China), ecnoglutide is the first GLP-1 receptor agonist intentionally optimized for cAMP signaling bias: it activates the Gs/adenylyl cyclase/cAMP cascade with an EC50 of 0.018 nM (comparable to semaglutide at 0.012 nM) while producing substantially reduced beta-arrestin recruitment (Emax approximately 54 to 60 percent of semaglutide, EC50 approximately 1300 nM) and negligible GLP-1 receptor internalization (EC50 greater than 10 micromolar versus 0.093 micromolar for semaglutide) [1]. The biased signaling profile preserves receptor surface density and downstream insulin secretion while reducing the desensitization, tachyphylaxis, and gastrointestinal adverse events theoretically attributable to beta-arrestin-mediated receptor endocytosis. In surface plasmon resonance binding studies, ecnoglutide demonstrates a dissociation constant (KD) of 1.45 nanomolar at the human GLP-1 receptor, approximately 10- to 30-fold higher affinity than semaglutide (KD 17.0 nanomolar) [1]. The compound consists exclusively of natural amino acids, simplifying the manufacturing process relative to semaglutide (which incorporates alpha-aminoisobutyric acid at position 8). Pharmacokinetics in healthy human volunteers support once-weekly subcutaneous dosing: the terminal elimination half-life at steady state ranges from 124 to 138 hours, with median time to peak concentration (Tmax) of 12 to 72 hours and dose-proportional plasma exposure across the studied dose range [1]. In the Phase 2 randomized, double-blind, placebo-controlled trial in 145 adults with type 2 diabetes, ecnoglutide at 0.4, 0.8, and 1.2 mg weekly for 20 weeks produced HbA1c reductions of 1.81, 1.90, and 2.39 percentage points, respectively, versus 0.55 points on placebo [2]. In the Phase 3 EECOH-1 trial of ecnoglutide monotherapy (0.6 mg and 1.2 mg weekly) in 211 patients with type 2 diabetes, up to 76.1 percent of patients in the 1.2 mg cohort achieved HbA1c targets of 6.5 percent or less [3]. In the Phase 3 EECOH-2 active-comparator trial, ecnoglutide 0.6 mg and 1.2 mg weekly demonstrated non-inferiority to dulaglutide 1.5 mg weekly on HbA1c reduction over 52 weeks, with the 1.2 mg dose achieving statistically significantly greater reduction [4]. In the Phase 3 SLIMMER trial in 664 adults with overweight or obesity without diabetes, ecnoglutide at 1.2, 1.8, and 2.4 mg weekly produced mean body weight reductions of 9.1, 10.9, and 13.2 percent, respectively, at 40 weeks versus 0.1 percent on placebo; at 48 weeks, the 2.4 mg dose achieved 15.4 percent mean weight loss, with 92.8 percent of participants achieving 5 percent or greater weight loss [5]. The safety profile is consistent with the GLP-1 receptor agonist class: the principal adverse events are gastrointestinal (nausea, diarrhea, decreased appetite), predominantly mild to moderate in severity, concentrated during the dose-escalation period, and diminishing over time. Hypoglycemia risk is low. China’s National Medical Products Administration (NMPA) approved ecnoglutide injection for chronic weight management in January 2026, making it the first approved cAMP-biased GLP-1 receptor agonist worldwide [6]. The compound is not approved by the United States Food and Drug Administration or by the European Medicines Agency as of the most recent monograph revision. This monograph reviews the chemistry, biased-agonist pharmacology, comprehensive pharmacokinetics, the clinical evidence base across type 2 diabetes and obesity indications, sourcing and quality considerations, reconstitution and handling, stack-interaction implications, adverse-event signal, and a comparative assessment of five GLP-1 receptor agonist and incretin mimetic candidates against ecnoglutide on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1411Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Ovagen

    Synthetic hepatoprotective tripeptide bioregulator of the Khavinson ultrashort peptide class

    A synthetic tripeptide (Glu-Asp-Leu) developed at the Saint Petersburg Institute of Bioregulation and Gerontology as a tissue-specific epigenetic bioregulator targeting hepatic and gastrointestinal gene expression, distinguished from conventional hepatoprotective agents by a proposed mechanism of direct nuclear peptide-DNA interaction and chromatin remodeling rather than receptor-mediated signal transduction.

    Abstract

    Ovagen is a synthetic tripeptide composed of L-glutamic acid, L-aspartic acid, and L-leucine (Glu-Asp-Leu; single-letter code EDL) and belongs to the Khavinson class of ultrashort peptide bioregulators developed at the Saint Petersburg Institute of Bioregulation and Gerontology under the direction of Vladimir Khavinson. The compound is classified as a liver and gastrointestinal tract bioregulator within the Cytogen (synthetic short-chain peptide) product line and is proposed to exert its biological activity through direct interaction with nuclear DNA and chromatin rather than through conventional membrane receptor signaling. The molecular weight of Ovagen is 375.37 daltons (molecular formula C15H25N3O8), a size that places it within the ultrashort peptide category (2 to 7 amino acid residues) characterized by resistance to gastrointestinal peptidase degradation, oral bioavailability without enteric coating in some formulations, and the capacity to cross cellular membranes and localize to the nucleoplasm without receptor-mediated endocytosis. The principal proposed mechanism of action involves sequence-specific binding of the EDL tripeptide to double-stranded DNA in the promoter regions of hepatocyte genes governing cell proliferation, antioxidant defense, apoptosis, and inflammatory signaling. In aged rat liver tissue, Ovagen administration has been reported to produce an approximately 18-fold increase in Ki-67 expression (a marker of cellular proliferation) and an approximately 6-fold decrease in p53 expression (a marker of apoptotic signaling and cellular senescence), suggesting a shift from senescent to proliferative hepatocyte phenotype [1, 2]. In preclinical models of chemically induced hepatotoxicity (carbon tetrachloride and paracetamol), Ovagen administration over 14 to 28 days reduced serum liver enzyme elevation, decreased hepatocyte necrosis and inflammatory cell infiltration on histological examination, and normalized hepatic antioxidant status [3, 4]. A secondary research application involves gastrointestinal mucosal support, with preclinical data suggesting that Ovagen strengthens epithelial barrier function, increases tight junction protein expression, and reduces intestinal permeability in aging models [5]. The compound has not been approved by any national regulatory authority for therapeutic use. No published, peer-reviewed human clinical trials of Ovagen exist as of the date of this monograph. The evidence base is entirely preclinical (cell culture and rodent models) and is derived predominantly from the Khavinson laboratory and collaborating Russian institutions. The peptide bioregulator framework within which Ovagen was developed has produced a substantial body of Russian-language and English-language literature, including a 2021 systematic review of peptide regulation of gene expression published in the journal Molecules [6], but the framework has not been independently validated by Western regulatory-standard clinical trials. Investigators considering Ovagen for research applications should weight the evidence accordingly, noting the predominantly single-laboratory provenance of the preclinical data, the absence of human pharmacokinetic characterization to Western regulatory standards, and the mechanistic novelty of the proposed direct peptide-DNA interaction pathway. This monograph reviews the chemistry, proposed mechanism of action, preclinical pharmacology, available pharmacokinetic considerations, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, adverse-event signal, and a comparative assessment of five hepatoprotective or liver-bioregulatory candidates against Ovagen on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1406Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Isoflurane

    Plain-language summaryIntrigue 60 / 100

    Isoflurane is a halogenated ether volatile anesthetic introduced in 1981 and the dominant inhalational agent of the 1990s before sevoflurane and desflurane displaced it. Its blood-gas partition coefficient sits in the middle of the class, giving moderately fast induction and emergence, slower than the modern agents but much faster than the old halothane. Mechanism is multifactorial and incompletely worked out: positive modulation of GABA-A receptors at sites distinct from benzodiazepine and barbiturate sites, activation of two-pore potassium channels, glycine receptor potentiation, and NMDA inhibition. Cardiovascular effects include dose-dependent vasodilation with preserved cardiac output. Hepatic metabolism is only 0.2 percent (versus 20 percent for halothane), so immune-mediated hepatitis is rare. Still widely used in veterinary anesthesia and lower-resource clinical settings where cost favors it over the newer agents. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Halogenated ether volatile general anesthetic

    A halogenated methyl ethyl ether introduced in 1981 that remained the dominant inhalational anesthetic of the 1990s before sevoflurane and desflurane displaced it.

    Abstract

    Isoflurane (1-chloro-2,2,2-trifluoroethyl difluoromethyl ether; CAS 26675-46-7; molecular formula C3H2ClF5O; molecular weight 184.49) is a halogenated methyl ethyl ether volatile anesthetic introduced clinically by Ohio Medical Products in 1981. The minimum alveolar concentration (MAC) at 40 years of age is 1.15 percent in oxygen and 0.5 percent in 70 percent nitrous oxide. The blood-gas partition coefficient is 1.4, intermediate between halothane (2.4) and the modern agents desflurane (0.42) and sevoflurane (0.65); this corresponds to moderately fast induction and emergence relative to halothane but substantially slower than desflurane. Mechanism is multifactorial and incompletely characterized: principal targets include positive allosteric modulation of GABA-A receptors at sites distinct from benzodiazepine and barbiturate sites, two-pore domain potassium channel (TREK-1, TASK) activation, glycine receptor potentiation, and inhibition of NMDA glutamate currents at clinically relevant partial pressures. Cardiovascular effects include dose-dependent reduction in systemic vascular resistance and modest negative inotropy with preserved cardiac output through reflex tachycardia; coronary vasodilation has been studied for steal physiology but the clinical significance is limited. Respiratory effects include dose-dependent depression of tidal volume with compensatory tachypnea. Hepatotoxicity through trifluoroacetylated protein adduct formation occurs in 0.2 percent of metabolism (versus 20 percent for halothane) and the clinical incidence of immune-mediated hepatitis is correspondingly low. Used widely in veterinary anesthesia and in lower-resource settings where acquisition cost favors isoflurane over the newer agents.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1301Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Memantine

    Plain-language summaryIntrigue 72 / 100

    Memantine, sold as Namenda, is an Alzheimer disease medication that blocks the NMDA glutamate receptor. Unlike most NMDA antagonists it has a brief, low-affinity profile that allows normal learning while preventing the chronic excitotoxicity associated with neurodegeneration. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Uncompetitive NMDA receptor antagonist with ancillary 5-HT3 antagonist and alpha-7 nicotinic receptor activity

    A 3,5-dimethyladamantane derivative developed by Merz Pharmaceuticals as a moderate-affinity, voltage-dependent, uncompetitive NMDA receptor open-channel blocker approved for moderate-to-severe Alzheimer’s disease, distinguished from high-affinity NMDA antagonists by rapid off-rate kinetics that permit preservation of physiological synaptic transmission while attenuating tonic excitotoxic glutamatergic signaling.

    Abstract

    Memantine (1-amino-3,5-dimethyladamantane; CAS 19982-08-2; molecular formula C12H21N; molecular weight 179.30) is a moderate-affinity, uncompetitive, voltage-dependent, open-channel blocker of the N-methyl-D-aspartate (NMDA) subtype of the ionotropic glutamate receptor, approved in the European Union (2002) and the United States (2003) for the treatment of moderate-to-severe Alzheimer’s disease. The compound is an adamantane derivative structurally related to the antiviral agent amantadine, first synthesized and patented by Eli Lilly and Company in 1968 as a potential antidiabetic agent, subsequently identified as possessing central nervous system activity in the early 1970s by Merz Pharmaceuticals, and characterized as an NMDA receptor channel blocker by Bormann in 1989 [1]. The pharmacological distinction of memantine from high-affinity NMDA channel blockers such as phencyclidine, dizocilpine (MK-801), and ketamine rests on three properties: moderate binding affinity (IC50 approximately 1 micromolar at resting membrane potential), strong voltage dependence that ensures rapid unblocking upon physiological depolarization, and fast open-channel blocking and unblocking kinetics (time constant of unblock approximately 5 seconds) [2, 3]. These kinetic properties allow memantine to attenuate the tonic, pathologically elevated glutamatergic signaling associated with excitotoxic neurodegeneration while preserving the transient, high-amplitude synaptic NMDA receptor activation required for long-term potentiation and normal cognitive function. In addition to the primary NMDA receptor mechanism, memantine acts as a non-competitive antagonist of the serotonin 5-HT3 receptor at concentrations comparable to its NMDA receptor affinity (IC50 approximately 1 to 2 micromolar) [4] and as a non-competitive antagonist of the alpha-7 nicotinic acetylcholine receptor (IC50 approximately 0.34 to 5 micromolar depending on assay conditions) [5]. Weak agonist activity at the sigma-1 receptor (Ki approximately 2.6 micromolar) has been reported but is unlikely to contribute at therapeutic plasma concentrations [6]. Pharmacokinetics in humans are characterized by near-complete oral bioavailability (approximately 100 percent), a long plasma elimination half-life of 60 to 80 hours permitting once- or twice-daily dosing, minimal hepatic cytochrome P450-mediated metabolism, and predominantly renal elimination with approximately 48 percent of the administered dose excreted unchanged in urine through pH-dependent tubular reabsorption and active tubular secretion [7, 8]. The compound is well tolerated at the approved dose of 20 mg per day; the principal adverse events in registration trials were dizziness, headache, confusion, and constipation, occurring at rates comparable to or modestly exceeding placebo [9, 10]. Two pivotal registration trials established efficacy: the Reisberg et al. (2003) study in 252 patients with moderate-to-severe Alzheimer’s disease demonstrated significant benefit over placebo on the Severe Impairment Battery (SIB) and the Clinician’s Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) over 28 weeks [9], and the Tariot et al. (2004) study in 404 patients already receiving stable donepezil demonstrated that the addition of memantine produced significant improvement in cognitive, functional, behavioral, and global measures compared to placebo plus donepezil [10]. Memantine is marketed as Namenda (Forest Laboratories, now Allergan/AbbVie) in the United States, as Axura (Merz) and Ebixa (Lundbeck) in Europe, and under multiple generic names globally. An extended-release formulation (Namenda XR, 28 mg once daily) was approved in 2010, and a fixed-dose combination of memantine extended-release and donepezil (Namzaric, 28 mg/10 mg) was approved in 2014. This monograph reviews the chemistry, synthesis, and structural pharmacology of memantine; the multi-target receptor pharmacology with emphasis on the NMDA receptor mechanism; comprehensive human pharmacokinetics; preclinical neuroprotection and cognition pharmacology; the clinical evidence base across Alzheimer’s disease, vascular dementia, neuropathic pain, and investigational indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse events and safety signal; and a comparative assessment of five therapeutic alternatives against memantine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1357Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Articaine

    Plain-language summaryIntrigue 55 / 100

    Articaine (Ultracain, Septocaine) is the dominant dental local anesthetic in much of Europe and increasingly in North America, structurally distinct from other amide locals in carrying both an amide and a methyl ester linkage on a thiophene ring. The methyl ester is rapidly hydrolyzed by plasma esterases to the inactive articainic acid metabolite, producing the shortest plasma half-life of any amide local anesthetic (about 25 minutes). That truncates systemic exposure during repeated dental infiltration. The thiophene ring confers enhanced bone diffusion, supporting the clinical perception that articaine produces effective infiltration anesthesia of mandibular molar teeth without requiring a full inferior alveolar nerve block. Sold as 4 percent solution with epinephrine 1:100,000 or 1:200,000. The principal safety considerations are mild methemoglobinemia risk and case reports of paresthesia after IAN block. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Amide local anesthetic with thiophene ring (dental)

    The dominant dental local anesthetic in much of Europe and increasingly in North America, distinguished by a thiophene ring enabling rapid plasma esterase hydrolysis.

    Abstract

    Articaine (methyl 4-methyl-3-(2-propylaminopropanoylamino)thiophene-2-carboxylate; CAS 23964-58-1; molecular formula C13H20N2O3S; molecular weight 284.38) is an amide local anesthetic developed by Hoechst in the 1970s and introduced in Germany in 1976 (Ultracain, Septocaine in North America). The compound is structurally distinct among amide local anesthetics in carrying both an amide and a methyl ester linkage on a thiophene ring rather than the dimethylphenyl ring of lidocaine and the pipecoloxylidide family. The methyl ester is rapidly hydrolyzed by plasma esterases to the inactive articainic acid metabolite (plasma half-life approximately 25 minutes, shorter than any other amide), which truncates systemic exposure and reduces accumulation risk during dental procedures requiring repeated infiltration. The thiophene ring confers enhanced bone diffusion, supporting the clinical perception that articaine produces effective infiltration anesthesia of mandibular molar teeth without requiring inferior alveolar nerve block in many cases (a clinical advantage that makes articaine the dominant dental anesthetic in much of Europe). Mechanism is voltage-gated sodium channel block; potency is approximately 1.5-fold that of lidocaine on infiltration. Articaine is sold as a 4 percent solution with epinephrine 1:100,000 or 1:200,000. The principal safety considerations are the same methemoglobinemia risk noted for prilocaine (articaine generates methemoglobin-inducing metabolites though at lower doses than prilocaine, the clinical risk is correspondingly low) and case reports of paresthesia after inferior alveolar nerve block. Maximum recommended dose is 7 mg/kg in adults and 5 mg/kg in children.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1316Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • TB-500 Fragment (LKKTETQ)

    Heptapeptide active fragment of thymosin beta-4

    A seven-residue actin-binding fragment of thymosin beta-4 (Tฮฒ4 residues 17 through 23), studied as the minimal active region driving the cell migration and angiogenic effects of the parent peptide.

    Abstract

    TB-500 Fragment (Leu-Lys-Lys-Thr-Glu-Thr-Gln; LKKTETQ; thymosin beta-4 residues 17 through 23; molecular weight 819.93) is a seven-residue synthetic peptide corresponding to the minimal actin-binding region of thymosin beta-4 (Tbeta4), the 43-residue actin-sequestering protein expressed at high concentration in platelets, leukocytes, and many other cell types. The full-length Tbeta4 sequence is the molecule supplied as Kodiac biolabs TB-500 (KDC-MN-003); the LKKTETQ fragment is a separate research-grade preparation that has been used in vendor literature and a limited research literature interchangeably with TB-500 (a confusion that should be resolved by mass spectrometry on each lot, since the fragment and full-length peptides have very different masses). The pharmacological argument for the heptapeptide is that LKKTETQ retains the cell migration and angiogenic activity of the parent at substantially lower molecular weight, with potentially favorable pharmacokinetic and tissue distribution profiles. Published in vitro and rodent studies support migration-promoting activity at this minimal sequence. The full-length Tbeta4 has additional activities (anti-inflammatory effects, regulation of cardiac and corneal repair) that depend on residues outside the 17-23 region and are not necessarily reproduced by the fragment. Investigators should specify whether the research-grade preparation in question is the full-length 43-residue peptide (KDC-MN-003) or the LKKTETQ heptapeptide (this monograph), since the published preclinical record is dominated by the full-length compound and translation of full-length results to fragment dosing should be done with caution. Reconstitution and handling parallel other small synthetic peptides; the heptapeptide is highly water-soluble and stable to lyophilization. Plasma half-life is on the order of minutes; tissue retention is shorter than for the full-length peptide.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1335Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.